Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?
Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?
大麻股票因DEA延遲重新分級下跌高達16%：這可能是2024年的購買機會嗎？
The U.S. Drug Enforcement Administration (DEA) announced a delay on Monday in its final ruling on cannabis rescheduling until after the November presidential election. The decision, which has created uncertainty in the market, pits Vice President Kamala Harris, a cannabis reform advocate, against former President Donald Trump, whose vice-presidential pick is opposed to legalization.
美國緝毒局（DEA）宣佈延遲對大麻重新分類的最終裁決，直到11月總統選舉結束後。該決定在市場上造成了不確定性，讓大麻改革倡導者、副總統賀錦麗與前總統特朗普的副總統候選人對立，後者反對合法化。
Market Responds With Sharp Declines
市場出現急劇下跌
According to Benzinga Pro, the market's response was immediate and pronounced. The AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) dropped over 10% in early trading, while individual cannabis stocks experienced significant declines.
根據Benzinga Pro的報道，市場立即做出了明顯的回應。AdvisorShares Pure US Cannabis ETF（紐交所:MSOS）在早盤交易中下跌超過10%，而個別大麻股票也出現了顯著下跌。
Amid the market downturn some of the...
在市場下行中，...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。